Let’s start up with the current stock price of Arbutus Biopharma Corporation (ABUS), which is $2.91 to be very precise. The Stock rose vividly during the last session to $2.80 after opening rate of $2.77 while the lowest price it went was recorded $2.72 before closing at $2.78.Recently in News on January 5, 2023, Arbutus Announces 2023 Corporate Objectives and Provides Financial Update. Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023. You can read further details here
Arbutus Biopharma Corporation had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.93 on 01/13/23, with the lowest value was $2.15 for the same time period, recorded on 01/05/23.
Arbutus Biopharma Corporation (ABUS) full year performance was 3.73%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arbutus Biopharma Corporation shares are logging -19.92% during the 52-week period from high price, and 57.57% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.85 and $3.64.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 858027 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arbutus Biopharma Corporation (ABUS) recorded performance in the market was 19.31%, having the revenues showcasing 31.75% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 416.08M, as it employees total of 85 workers.
The Analysts eye on Arbutus Biopharma Corporation (ABUS)
During the last month, 0 analysts gave the Arbutus Biopharma Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.38, with a change in the price was noted +0.64. In a similar fashion, Arbutus Biopharma Corporation posted a movement of +28.83% for the period of last 100 days, recording 910,469 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABUS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Arbutus Biopharma Corporation (ABUS)
Raw Stochastic average of Arbutus Biopharma Corporation in the period of last 50 days is set at 91.33%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 91.33%. In the last 20 days, the company’s Stochastic %K was 83.61% and its Stochastic %D was recorded 78.75%.
Considering, the past performance of Arbutus Biopharma Corporation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 19.31%. Additionally, trading for the stock in the period of the last six months notably improved by 15.35%, alongside a boost of 3.73% for the period of the last 12 months. The shares increased approximately by -0.71% in the 7-day charts and went down by 15.83% in the period of the last 30 days. Common stock shares were driven by 31.75% during last recorded quarter.